 |

The estrogen plus progestin trial was stopped in July 2002, after investigators found that the associated health risks of the combination hormone therapy outweighed the benefits. Participants were followed for an average of 5.6 years.
Selected Findings
Health Risks and Benefits 3 Years After Stopping (March 2008)
Venous Thrombosis (October 2004)
Colorectal Cancer (March 2004)
Peripheral Arterial Disease Risk (February
2004)
Fracture Risk and Bone Mineral Density (October 2003)
Gynecologic Cancers and Diagnostic Procedures (October 2003)
Coronary Heart Disease Risk (August 2003)
Breast Cancer Risk (June 2003)
Dementia and Cognitive Function -- Women's Health Initiative Memory Study (May 2003)
- Press release: Rates of Dementia Increase Among Older Women on Combination Hormone Therapy, May 27, 2003
- Questions and Answers About the Women's Health Initiative Memory Study
- Women's Health Initiative Memory Study Web site
- FDA Talk Paper
- Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women, JAMA, May 28, 2003
- Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women, JAMA, May 28, 2003
- Hormone Therapy and the Brain Ç D»j› vu All Over Again? (Editorial), JAMA, May 28, 2003
Stroke Risk (May 2003)
Quality of life (March 2003)
Risks and Benefits of Combination Therapy (July 2002)
|